Search bioRxiv⌕ Search

Biology subjects

Delogu, L. G.

Publications and source records attributed to Delogu, L. G..

2 recordsLinked to original sources

Predicting the Reprogrammability of Human Cells Based on Transcriptome Data and SGD Classifier with Elastic-Net Regularization

Cell reprogramming has shown considerable importance in recent years; however, the programmability of cells and efficiency of reprogramming varies across different cell types. Considering several weeks of cell programming process and costly programming agents used through the process, every failure in reprogramming comes with a significant burden. Better planning for reprogramming experiments could be possible if there is a way of predicting the outcome of reprogramming before the experiments using transcriptome data. In this study, we have accessed the transcriptome data of successful or unsuccessful programming studies published in literature and constructed a Stochastic Gradient Descent (SGD) classifier with Elastic-Net regularization for predicting whether the cell lines are reprogrammable. We tested our classifier using 10-fold cross validation over cell lines and on each cell separately. Our results showed that it is possible to predict the outcome of cell reprogramming with accuracies up to 98% and Area Under the Curve (AUC) scores up to 0.98%. Considering the success of our experimental outcomes we conclude that an outcome of a cell reprogramming experiment can be predicted with high accuracy using machine learning on transcriptome data.

bioengineering↗

Favipiravir, umifenovir and camostat mesylate: a comparative study against SARS-CoV-2

Since the first cases the coronavirus disease caused by SARS-CoV-2 (COVID-19) reported in December 2019, worldwide continuous efforts have been placed both for the prevention and treatment of this infectious disease. As new variants of the virus emerge, the need for an effective antiviral treatment continues. The concept of preventing SARS-CoV-2 on both pre-entry and post-entry stages has not been much studied. Therefore, we compared the antiviral activities of three antiviral drugs which have been currently used in the clinic. In silico docking analyses and in vitro viral infection in Vero E6 cells were performed to delineate their antiviral effectivity when used alone or in combination. Both in silico and in vitro results suggest that the combinatorial treatment by favipiravir and umifenovir or camostat mesylate has more antiviral activity against SARS-CoV-2 rather than single drug treatment. These results suggest that inhibiting both viral entry and viral replication at the same time is much more effective for the antiviral treatment of SARS-CoV-2.

pharmacology and toxicology↗